STOCK TITAN

Resmed Inc. - RMD STOCK NEWS

Welcome to our dedicated news page for Resmed (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Resmed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Resmed's position in the market.

Rhea-AI Summary
ResMed (NYSE: RMD, ASX: RMD) announced a new operating model to accelerate long-term growth, introducing dedicated leadership in Product, Revenue, and Marketing to the global executive team. The change aims to increase product development velocity and sharpen customer and brand focus, ultimately accelerating profitable growth and driving greater value and improved care throughout the patient journey.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
-
Rhea-AI Summary
ResMed announces Q1 2024 results with 16% YoY revenue growth and 5% increase in operating profit. Expects to resume share repurchase program. CEO confident in growth strategy. Webcast available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
-
Rhea-AI Summary
ResMed to release Q1 FY2024 financial results on October 26, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
conferences earnings
Rhea-AI Summary
ResMed to participate in two upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.5%
Tags
-
Rhea-AI Summary
ResMed (NYSE: RMD, ASX: RMD) will release its financial and operational results for Q4 of FY2023 on August 3, 2023. The company will host a webcast to discuss the results, including forward-looking information. The webcast details are available on ResMed's investor website. A replay of the webcast will be accessible on the company's website, and a phone replay will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
partnership AI
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
Resmed Inc.

NYSE:RMD

RMD Rankings

RMD Stock Data

27.34B
145.65M
0.82%
57.19%
5.37%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
San Diego

About RMD

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.